NCT05183971 Proprioceptive Deficits in Degenerative Cervical Myelopathy
| NCT ID | NCT05183971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Cervical Myelopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2040-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-09-01 with a primary completion date of 2040-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Proprioceptive deficits in degenerative cervical myelopathy (DCM) is a progressive neurological deficits in somatosensory and motor function which affects the body balance and motor control. DCM usually presents with body incoordination, hand clumsiness and gait disturbance associated with proprioceptive dysfunction that hinders the physical performance and functions. In this study, a non-invasive assessment protocol on proprioception will be developed for detecting subtle proprioceptive deficits at the early stage of disease through simple Physical Performance Tests for population older than 45. By adopting the physical performance tests as the diagnostic predictors of DCM, we aim to avoid the development of devastating consequences and disabilities.
Eligibility Criteria
Inclusion Criteria: * Chinese * Aged 50 or above * With radiological evidence of degenerative cervical myelopathy, both symptomatic and asymptomatic * Nurick grade less than 3 Exclusion Criteria: * Non-Chinese ethnicity * Aged under 50 * without any radiological proof of cervical myelopathy * Active problems of tuberculosis spine, lumbar spinal diseases, and other problems causing pain or deformities over the limbs that may affect their balance and movement * Presents with extra-pyramidal or other disorders involving the cerebellum or frontal lobe of the cerebrum leading to poor balance and gait disturbance * Previous spinal operation with residual disturbance in balance or gait * Non-communicable patients with insufficient cognitive ability to express their symptoms clearly * Non-walker * Blind or deaf
Contact & Investigator
Karlen Ka Pui Law, M. Phil
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT05183971 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Cervical Myelopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05183971 currently recruiting?
Yes, NCT05183971 is actively recruiting participants. Contact the research team at karlenhk@connect.com.hk for enrollment information.
Where is the NCT05183971 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT05183971 clinical trial?
NCT05183971 is sponsored by The University of Hong Kong. The principal investigator is Karlen Ka Pui Law, M. Phil at The University of Hong Kong. The trial plans to enroll 100 participants.